FINM3005 · Corporate Valuation
Sum-of-the-Parts and M&A
This chapter applies the valuation engine to two structures where a single company-wide DCF breaks down: multi-business firms and acquisitions. Sum-of-the-parts (SOTP) treats a multi-business firm as a portfolio — its segments differ in growth, risk and returns, so a single blanket WACC over-discounts the low-risk arm and under-discounts the high-risk one, and the errors do not cancel. You value each segment on its own terms (DCF where you can build segment statements, multiples where disclosure is thin), give each its own segment WACC from single-business peers, add a usually-negative corporate centre and excess cash, then bridge to equity; the gap between the SOTP total and market cap is the conglomerate discount. M&A valuation treats an acquisition as just another investment: the single test is whether the value you receive — the synergy — exceeds the premium you pay over the target's standalone value (NPV = synergy − premium > 0). You value synergy as the PV of incremental after-tax cash flow, handle cash vs stock and the exchange ratio, and confront the most-baited trap in the topic: EPS accretion is not value creation — a deal can be accretive yet value-destroying, or dilutive yet value-creating.
What this chapter covers
- 01Sum-of-the-parts: value each segment at its own WACC
- 02The corporate centre and the conglomerate discount
- 03When SOTP beats a single consolidated DCF
- 04M&A: forms of acquisition and the value identity
- 05The synergy > premium test and valuing synergy
- 06Cash vs stock, the exchange ratio and goodwill
- 07Accretion / dilution — and why it is not value creation
Worked example: the M&A value test and the accretion trap
- +1(a) Premium. Price paid − target standalone = 720 − 600 = $120m.
- +1NPV to acquirer. Synergy − premium = 180 − 120 = +$60m → the deal creates value (synergy > premium).
- +1(b) Exchange ratio. ER = Pₛ / Pₐ = 7.50 / 12.00 = 0.625 acquirer shares per target share; issue 0.625 × 80m = 50m new shares → total 250m.
- +1Pro-forma EPS. Combined net income (pre-synergy) = 160 + 48 = $208m over 250m shares = $0.832 vs the acquirer's standalone $0.80 → the deal is EPS-accretive (+4%).
- +1Why accretive? The acquirer's P/E (15×) exceeds the target's implied P/E (600/48 = 12.5×) — buying a lower-P/E currency is mechanically accretive.
- +1(c) The trap. No — accretion is not value creation. EPS can rise even if synergy < premium; you have simply bought cheaper earnings. The value verdict is synergy vs premium (here +$60m), not the EPS sign.
Key terms
- Sum-of-the-parts (SOTP)
- Valuing a multi-business firm segment by segment — each by DCF or multiples, each at its own segment WACC from single-business peers — then summing segment EVs, a usually-negative corporate centre, and excess cash to a gross EV before bridging to equity. Used when segments differ materially in risk/growth, a break-up is plausible, or different segments suit different methods.
- Conglomerate discount
- The tendency of diversified firms to trade at roughly 90–95% of the sum of their standalone segment values, reflecting complexity, weaker capital allocation and harder analysis. The gap between an SOTP total and market cap is this discount; a break-up or spin-off that releases it is the SOTP investment thesis.
- Synergy
- Value created above the simple sum of the two firms' standalone values (ΔV), estimated as the PV of incremental after-tax cash flow — low-risk cost savings discounted near the cost of debt, risky revenue synergies at the WACC. Standalone improvements you could make without the deal are not synergy.
- Premium and the value test
- The premium is price paid minus the target's standalone (pre-bid) value — what you pay for control. The M&A value test is NPV = synergy − premium > 0, i.e. value is created only when synergy exceeds the premium. The control premium is not synergy: paying a 20% premium does not create 20% of synergy.
- Accretion vs value creation
- EPS accretion means pro-forma EPS rises; it reflects the relative P/E of the currency used (a higher-P/E acquirer buying a lower-P/E target is mechanically accretive) and says nothing about whether the new capital earns above the WACC. A deal can be accretive yet value-destroying, or dilutive yet value-creating — the test is synergy vs premium, never the EPS sign.
Sum-of-the-Parts and M&A FAQ
Why give each segment its own WACC instead of one group WACC?
Because segments differ in risk and growth, so a single blanket WACC over-discounts a low-risk arm (under-valuing it) and under-discounts a high-risk arm (over-valuing it), and the two errors do not cancel — they depend on each arm's cash-flow timing and size. Estimating each segment's WACC from single-business peers (unlever their betas, relever at the segment's leverage) removes the bias. This is the payoff of the comparable-beta machinery from the cost-of-capital chapter.
What is the conglomerate discount and what do I do with it?
Diversified firms typically trade at ~90–95% of the sum of their standalone values — the market pricing complexity, weaker capital allocation and harder analysis. If an SOTP total is, say, $2,500m against a market cap of $2,300m, the ~8% gap is the conglomerate discount. A break-up or spin-off that releases the trapped value is the investment thesis the SOTP supports.
When does an acquisition create value?
Only when the synergy you receive exceeds the premium you pay over the target's standalone value: NPV = synergy − premium > 0. Empirically targets win (premiums almost always accrue to them) while acquirers earn roughly zero on average, because they overpay the premium away. Value synergy as the PV of incremental after-tax cash flow, and do not count standalone improvements you could make without the deal.
Why is EPS accretion not the same as value creation?
Because EPS accretion just reflects the relative P/E of the currency used — a higher-P/E acquirer buying a lower-P/E target is mechanically accretive regardless of whether the deal earns above the WACC. A deal can be EPS-accretive yet value-destroying (premium > synergy) or dilutive yet value-creating. This is the most-baited M&A trap; always answer with the synergy-minus-premium NPV, not the EPS sign.
Exam move
Run SOTP as a four-line routine: value each segment (DCF or multiples) at its own WACC, add a negative corporate centre and excess cash for gross EV, bridge minus net debt to equity, then compare the total to market cap to read the conglomerate discount. Never forget the corporate-centre line — skipping it overstates EV. For M&A, lead with the single test (NPV = synergy − premium) and value synergy as the PV of after-tax incremental cash flow, splitting reliable cost savings from risky revenue synergies. Drill the accretion trap until it is reflexive: compute pro-forma EPS, then ignore its sign for the value verdict and answer with synergy vs premium. For stock deals, find the exchange ratio (Pₛ/Pₐ) and value both firms. The two headline traps to recite back — control premium ≠ synergy, accretion ≠ value — are where the marks live.
